Immuno-oncology therapy developer Intensity Therapeutics has added a $10m SalvaRx-backed round to $2.25m of earlier financing.

US-based cancer immunotherapy developer Intensity Therapeutics has raised $10m in a series preferred stock financing that included virtual drug developer SalvaRx Group.

The round also featured Batterson Venture Capital, VCapital, FastForward Innovations, angel investors Declan Doogan and Jim Mellon, and undisclosed family offices and other investors.

Intensity is working on immune-oncology drugs based on its DfuseRxSM platform, and the company claims its lead product candidate, INT230-6, is capable of completely clearing large tumours in animal testing.

Lewis H. Bender, Intensity’s…